Ganglionic nicotinic acetylcholine receptor (nAChR) (nAChR)

The ganglionic nicotinic acetylcholine receptor (nAChR) is a pentameric ligand-gated ion channel, most commonly composed of alpha3 (CHRNA3) and beta4 (CHRNB4) subunits (UniProt P32297, P30926). It is primarily localized in the postsynaptic membranes of neurons within the sympathetic and parasympathetic ganglia, where it mediates fast excitatory synaptic transmission (IUPHAR/BPS Guide to Pharmacology). Upon binding of acetylcholine, the receptor undergoes a conformational change that opens a cation-selective pore, leading to membrane depolarization and the propagation of action potentials in postganglionic neurons. This receptor is a critical regulator of involuntary physiological processes, including heart rate, blood pressure, and gastrointestinal motility (StatPearls NBK541055). In clinical medicine, it is the primary target in autoimmune autonomic ganglionopathy (AAG), a condition where autoantibodies against the alpha3 subunit impair ganglionic transmission, leading to severe autonomic failure (Mayo Clinic Laboratories). Historically, ganglionic blockers like mecamylamine and trimetaphan were used as potent antihypertensives, though their clinical utility is now restricted due to widespread side effects resulting from broad autonomic inhibition. Modern research also explores the receptor's role in nicotine addiction and its potential as a target for smoking cessation and neurodegenerative therapies.

Other names

Alpha-3/beta-4 nicotinic acetylcholine receptorNeuronal acetylcholine receptor ganglionic subtypePeripheral neuronal nicotinic receptorAlpha3-containing nicotinic receptor

Drugs targeting this receptor act as either agonists (activating the receptor to mimic acetylcholine) or antagonists (blocking the receptor to inhibit autonomic transmission). Ganglionic blockers typically act as non-competitive or competitive antagonists to reduce sympathetic and parasympathetic outflow.